Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 188

1.

Prevalence of refractory hypertension in the United States from 1999 to 2014.

Buhnerkempe MG, Botchway A, Prakash V, Al-Akchar M, Nolasco Morales CE, Calhoun DA, Flack JM.

J Hypertens. 2019 May 1. doi: 10.1097/HJH.0000000000002103. [Epub ahead of print]

PMID:
31058798
2.

Resistant Hypertension: An Update.

Calhoun DA, Schiffrin EL, Flack JM.

Am J Hypertens. 2019 Jan 1;32(1):1-3. doi: 10.1093/ajh/hpy156. No abstract available.

PMID:
30407514
3.

Predicting the risk of apparent treatment-resistant hypertension: a longitudinal, cohort study in an urban hypertension referral clinic.

Buhnerkempe MG, Botchway A, Nolasco Morales CE, Prakash V, Hedquist L, Flack JM.

J Am Soc Hypertens. 2018 Nov;12(11):809-817. doi: 10.1016/j.jash.2018.09.006. Epub 2018 Sep 20.

PMID:
30392848
4.

Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.

Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, Egan BM, Flack JM, Gidding SS, Judd E, Lackland DT, Laffer CL, Newton-Cheh C, Smith SM, Taler SJ, Textor SC, Turan TN, White WB; American Heart Association Professional/Public Education and Publications Committee of the Council on Hypertension; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Genomic and Precision Medicine; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research; and Stroke Council.

Hypertension. 2018 Nov;72(5):e53-e90. doi: 10.1161/HYP.0000000000000084.

5.

The New ACC/AHA Hypertension Guidelines for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults.

Flack JM, Calhoun D, Schiffrin EL.

Am J Hypertens. 2018 Jan 12;31(2):133-135. doi: 10.1093/ajh/hpx207. No abstract available.

PMID:
29228096
6.

Method of Blood Pressure Measurement, Interpretation of SPRINT, and the Atlantic Divide.

Flack JM.

Curr Hypertens Rep. 2017 Mar;19(3):19. doi: 10.1007/s11906-017-0719-0. Review. No abstract available.

PMID:
28271417
7.

Update From the Editors to Our Readers.

Schiffrin EL, Calhoun DA, Flack JM, Ito S, Webb RC.

Am J Hypertens. 2017 Jan;30(1):1-2. No abstract available.

PMID:
27940428
8.

Total antihypertensive therapeutic intensity score and its relationship to blood pressure reduction.

Levy PD, Willock RJ, Burla M, Brody A, Mahn J, Marinica A, Nasser SA, Flack JM.

J Am Soc Hypertens. 2016 Dec;10(12):906-916. doi: 10.1016/j.jash.2016.10.005. Epub 2016 Oct 28.

9.

Screening and Treatment for Subclinical Hypertensive Heart Disease in Emergency Department Patients With Uncontrolled Blood Pressure: A Cost-effectiveness Analysis.

Twiner MJ, Marinica AL, Kuper K, Goodman A, Mahn JJ, Burla MJ, Brody AM, Carroll JA, Josiah Willock R, Flack JM, Nasser SA, Levy PD.

Acad Emerg Med. 2017 Feb;24(2):168-176. doi: 10.1111/acem.13122. Epub 2017 Jan 30.

10.

A Novel Approach for Estimating Cost-Effectiveness of Pharmacological Treatment in Drug Naïve Adults with Hypertension.

Flack JM.

Am J Hypertens. 2016 Oct;29(10):1138-9. doi: 10.1093/ajh/hpw090. Epub 2016 Sep 1. No abstract available.

11.

The Case for Low Blood Pressure Targets.

Flack JM, Nolasco C, Levy P.

Am J Hypertens. 2017 Jan;30(1):3-7. Epub 2016 Aug 29. Review.

12.

Reducing Health Inequities in the U.S.: Recommendations From the NHLBI's Health Inequities Think Tank Meeting.

Sampson UKA, Kaplan RM, Cooper RS, Diez Roux AV, Marks JS, Engelgau MM, Peprah E, Mishoe H, Boulware LE, Felix KL, Califf RM, Flack JM, Cooper LA, Gracia JN, Henderson JA, Davidson KW, Krishnan JA, Lewis TT, Sanchez E, Luban NL, Vaccarino V, Wong WF, Wright JT Jr, Meyers D, Ogedegbe OG, Presley-Cantrell L, Chambers DA, Belis D, Bennett GC, Boyington JE, Creazzo TL, de Jesus JM, Krishnamurti C, Lowden MR, Punturieri A, Shero ST, Young NS, Zou S, Mensah GA.

J Am Coll Cardiol. 2016 Aug 2;68(5):517-524. doi: 10.1016/j.jacc.2016.04.059. Review.

13.

Do We Need a New Definition of Hypertension After SPRINT?

Schiffrin EL, Calhoun DA, Flack JM.

Am J Hypertens. 2016 Oct;29(10):1127-9. doi: 10.1093/ajh/hpw068. Epub 2016 Jun 22. No abstract available.

PMID:
27334926
14.

Impact of Renal Denervation on Patients With Obstructive Sleep Apnea and Resistant Hypertension - Insights From the SYMPLICITY HTN-3 Trial.

Kario K, Bhatt DL, Kandzari DE, Brar S, Flack JM, Gilbert C, Oparil S, Robbins M, Townsend RR, Bakris G.

Circ J. 2016 May 25;80(6):1404-12. doi: 10.1253/circj.CJ-16-0035. Epub 2016 Apr 26.

15.

A preliminary experimental examination of worldview verification, perceived racism, and stress reactivity in African Americans.

Lucas T, Lumley MA, Flack JM, Wegner R, Pierce J, Goetz S.

Health Psychol. 2016 Apr;35(4):366-75. doi: 10.1037/hea0000284.

16.

The Authors Reply, "as-needed intravenous antihypertensive therapy and blood pressure control".

Flack JM, Moser LR, Lipari M, Petrovitch E, Farber M.

J Hosp Med. 2016 Jul;11(7):526. doi: 10.1002/jhm.2565. Epub 2016 Feb 26. No abstract available.

17.

Genetic African Ancestry and Markers of Mineral Metabolism in CKD.

Gutiérrez OM, Parsa A, Isakova T, Scialla JJ, Chen J, Flack JM, Nessel LC, Gupta J, Bellovich KA, Steigerwalt S, Sondheimer JH, Wright JT Jr, Feldman HI, Kusek JW, Lash JP, Wolf M.

Clin J Am Soc Nephrol. 2016 Apr 7;11(4):653-62. doi: 10.2215/CJN.08020715. Epub 2016 Feb 8.

18.

Prevalence and Prognostic Significance of Apparent Treatment Resistant Hypertension in Chronic Kidney Disease: Report From the Chronic Renal Insufficiency Cohort Study.

Thomas G, Xie D, Chen HY, Anderson AH, Appel LJ, Bodana S, Brecklin CS, Drawz P, Flack JM, Miller ER 3rd, Steigerwalt SP, Townsend RR, Weir MR, Wright JT Jr, Rahman M; CRIC Study Investigators.

Hypertension. 2016 Feb;67(2):387-96. doi: 10.1161/HYPERTENSIONAHA.115.06487. Epub 2015 Dec 28.

19.

A Message From the New Editorial Team at the American Journal of Hypertension.

Schiffrin EL, Calhoun DA, Flack JM, Ito S, Webb RC.

Am J Hypertens. 2016 Jan;29(1):1. doi: 10.1093/ajh/hpv173. Review. No abstract available.

PMID:
26658829
20.

SPRINT Proves that Lower Is Better for Nondiabetic High-Risk Patients, but at a Price.

Schiffrin EL, Calhoun DA, Flack JM.

Am J Hypertens. 2016 Jan;29(1):2-4. doi: 10.1093/ajh/hpv190. Epub 2015 Nov 23. No abstract available.

PMID:
26597221
21.

As-needed intravenous antihypertensive therapy and blood pressure control.

Lipari M, Moser LR, Petrovitch EA, Farber M, Flack JM.

J Hosp Med. 2016 Mar;11(3):193-8. doi: 10.1002/jhm.2510. Epub 2015 Nov 12.

PMID:
26560085
22.

Prevalence, Predictors, and Outcomes of Pulmonary Hypertension in CKD.

Navaneethan SD, Roy J, Tao K, Brecklin CS, Chen J, Deo R, Flack JM, Ojo AO, Plappert TJ, Raj DS, Saydain G, Sondheimer JH, Sood R, Steigerwalt SP, Townsend RR, Dweik RA, Rahman M; Chronic Renal Insufficiency Cohort Investigators.

J Am Soc Nephrol. 2016 Mar;27(3):877-86. doi: 10.1681/ASN.2014111111. Epub 2015 Sep 18.

23.

An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial.

Flack JM, Bhatt DL, Kandzari DE, Brown D, Brar S, Choi JW, D'Agostino R, East C, Katzen BT, Lee L, Leon MB, Mauri L, O'Neill WW, Oparil S, Rocha-Singh K, Townsend RR, Bakris G; SYMPLICITY HTN-3 Investigators.

J Am Soc Hypertens. 2015 Oct;9(10):769-779. doi: 10.1016/j.jash.2015.08.001. Epub 2015 Aug 8.

PMID:
26362830
24.

Blood pressure treatment and outcomes in hypertensive patients without acute target organ damage: a retrospective cohort.

Levy PD, Mahn JJ, Miller J, Shelby A, Brody A, Davidson R, Burla MJ, Marinica A, Carroll J, Purakal J, Flack JM, Welch RD.

Am J Emerg Med. 2015 Sep;33(9):1219-24. doi: 10.1016/j.ajem.2015.05.036. Epub 2015 May 30.

PMID:
26087706
25.

Safety and efficacy of antihypertensive prescription at emergency department discharge.

Brody A, Rahman T, Reed B, Millis S, Ference B, Flack JM, Levy PD.

Acad Emerg Med. 2015 May;22(5):632-5. doi: 10.1111/acem.12660. Epub 2015 Apr 22.

26.

12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial.

Bakris GL, Townsend RR, Flack JM, Brar S, Cohen SA, D'Agostino R, Kandzari DE, Katzen BT, Leon MB, Mauri L, Negoita M, O'Neill WW, Oparil S, Rocha-Singh K, Bhatt DL; SYMPLICITY HTN-3 Investigators.

J Am Coll Cardiol. 2015 Apr 7;65(13):1314-1321. doi: 10.1016/j.jacc.2015.01.037.

27.
28.

Predictors of blood pressure response in the SYMPLICITY HTN-3 trial.

Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, Flack JM, Katzen BT, Lea J, Lee DP, Leon MB, Ma A, Massaro J, Mauri L, Oparil S, O'Neill WW, Patel MR, Rocha-Singh K, Sobotka PA, Svetkey L, Townsend RR, Bakris GL.

Eur Heart J. 2015 Jan 21;36(4):219-27. doi: 10.1093/eurheartj/ehu441. Epub 2014 Nov 16.

29.

Primary care in the emergency department -- an untapped resource for public health research and innovation.

Brody AM, Murphy E, Flack JM, Levy PD.

West Indian Med J. 2014 Jun;63(3):234-7. doi: 10.7727/wimj.2013.332. Epub 2014 Jun 11.

30.

Test characteristics of electrocardiography for detection of left ventricular hypertrophy in asymptomatic emergency department patients with hypertension.

Mahn JJ, Dubey E, Brody A, Welch R, Zalenski R, Flack JM, Ference B, Levy PD.

Acad Emerg Med. 2014 Sep;21(9):996-1002. doi: 10.1111/acem.12462.

31.

Utility of Framingham risk score in urban emergency department patients with asymptomatic hypertension.

Brody AM, Flack JM, Ference BA, Levy PD.

Crit Pathw Cardiol. 2014 Sep;13(3):114-6. doi: 10.1097/HPC.0000000000000016.

32.

Is evening dosing of antihypertensive therapy ready for prime time?

Flack JM.

J Clin Hypertens (Greenwich). 2014 Aug;16(8):557-8. doi: 10.1111/jch.12355. Epub 2014 Jun 23. No abstract available.

33.

Proceedings from Duke resistant hypertension think tank.

Vemulapalli S, Ard J, Bakris GL, Bhatt DL, Brown AS, Cushman WC, Ferdinand KC, Flack JM, Fleg JL, Katzen BT, Kostis JB, Oparil S, Patel CB, Pepine CJ, Piña IL, Rocha-Singh KJ, Townsend RR, Peterson ED, Califf RM, Patel MR.

Am Heart J. 2014 Jun;167(6):775-88.e1. doi: 10.1016/j.ahj.2014.02.008. Epub 2014 Feb 28.

PMID:
24890525
34.

Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3.

Bakris GL, Townsend RR, Liu M, Cohen SA, D'Agostino R, Flack JM, Kandzari DE, Katzen BT, Leon MB, Mauri L, Negoita M, O'Neill WW, Oparil S, Rocha-Singh K, Bhatt DL; SYMPLICITY HTN-3 Investigators.

J Am Coll Cardiol. 2014 Sep 16;64(11):1071-8. doi: 10.1016/j.jacc.2014.05.012. Epub 2014 May 20.

35.

Blood pressure control and perceived health status in African Americans with subclinical hypertensive heart disease.

Burla MJ, Brody AM, Ference BA, Flack JM, Mahn JJ, Marinica AL, Carroll JA, Nasser SA, Zhang S, Levy PD.

J Am Soc Hypertens. 2014 May;8(5):321-9. doi: 10.1016/j.jash.2014.02.010. Epub 2014 Feb 25.

PMID:
24726098
36.

A controlled trial of renal denervation for resistant hypertension.

Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL; SYMPLICITY HTN-3 Investigators.

N Engl J Med. 2014 Apr 10;370(15):1393-401. doi: 10.1056/NEJMoa1402670. Epub 2014 Mar 29.

37.

Clinical effect of naturally random allocation to lower systolic blood pressure beginning before the development of hypertension.

Ference BA, Julius S, Mahajan N, Levy PD, Williams KA Sr, Flack JM.

Hypertension. 2014 Jun;63(6):1182-8. doi: 10.1161/HYPERTENSIONAHA.113.02734. Epub 2014 Mar 3.

PMID:
24591335
38.

Should African Americans with hypertension be treated differently than non-African Americans?

Flack JM, Ference BA, Levy P.

Curr Hypertens Rep. 2014 Jan;16(1):409. doi: 10.1007/s11906-013-0409-5. Review.

PMID:
24370966
39.

Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension.

Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, Flack JM, Carter BL, Materson BJ, Ram CV, Cohen DL, Cadet JC, Jean-Charles RR, Taler S, Kountz D, Townsend RR, Chalmers J, Ramirez AJ, Bakris GL, Wang J, Schutte AE, Bisognano JD, Touyz RM, Sica D, Harrap SB.

J Clin Hypertens (Greenwich). 2014 Jan;16(1):14-26. doi: 10.1111/jch.12237. Epub 2013 Dec 17. No abstract available.

40.

Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension.

Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, Flack JM, Carter BL, Materson BJ, Ram CV, Cohen DL, Cadet JC, Jean-Charles RR, Taler S, Kountz D, Townsend R, Chalmers J, Ramirez AJ, Bakris GL, Wang J, Schutte AE, Bisognano JD, Touyz RM, Sica D, Harrap SB.

J Hypertens. 2014 Jan;32(1):3-15. doi: 10.1097/HJH.0000000000000065. No abstract available.

PMID:
24270181
41.

Should African-Americans with elevated blood pressure be routinely screened for hypertensive heart disease?

Levy PD, Flack JM.

Expert Rev Cardiovasc Ther. 2012 Oct;10(10):1201-4. doi: 10.1586/erc.12.130. No abstract available.

PMID:
23190057
42.

Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis.

Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A, Kahn J, Afonso L, Williams KA Sr, Flack JM.

J Am Coll Cardiol. 2012 Dec 25;60(25):2631-9. doi: 10.1016/j.jacc.2012.09.017. Epub 2012 Oct 17. Review.

43.

Should African Americans have a lower blood pressure goal than other ethnic groups to prevent organ damage?

Flack JM, Okwuosa T, Sudhakar R, Ference B, Levy P.

Curr Cardiol Rep. 2012 Dec;14(6):660-6. doi: 10.1007/s11886-012-0314-6.

PMID:
23065361
44.

Vitamin D and Parathyroid Hormone Relationships with Urinary Nitric Oxide Metabolites and Plasma Isoprostanes in African-Americans.

Valiña-Tóth AL, Lai Z, Zhang S, Flack JM.

Cardiorenal Med. 2012 Aug;2(3):234-242. Epub 2012 Jul 24.

45.

Relationship of resistant hypertension and treatment outcomes with total arterial compliance in a predominantly African American hypertensive cohort.

Bakhtar O, Ference BA, Hedquist LA, Levy PD, Flack JM.

J Clin Hypertens (Greenwich). 2012 Sep;14(9):618-22. doi: 10.1111/j.1751-7176.2012.00653.x. Epub 2012 May 18.

46.

Efficacy/safety of olmesartan medoxomil versus losartan potassium in patients by stage 1 or 2 hypertension.

Flack JM, Graff A, Li W, Chavanu KJ.

Postgrad Med. 2012 May;124(3):59-70. doi: 10.3810/pgm.2012.05.2549.

PMID:
22691900
47.

Subclinical hypertensive heart disease in black patients with elevated blood pressure in an inner-city emergency department.

Levy P, Ye H, Compton S, Zalenski R, Byrnes T, Flack JM, Welch R.

Ann Emerg Med. 2012 Oct;60(4):467-74.e1. doi: 10.1016/j.annemergmed.2012.03.030. Epub 2012 May 31. Erratum in: Ann Emerg Med. 2013 Jan;61(1):61.

PMID:
22658278
48.

Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial.

Kandzari DE, Bhatt DL, Sobotka PA, O'Neill WW, Esler M, Flack JM, Katzen BT, Leon MB, Massaro JM, Negoita M, Oparil S, Rocha-Singh K, Straley C, Townsend RR, Bakris G.

Clin Cardiol. 2012 Sep;35(9):528-35. doi: 10.1002/clc.22008. Epub 2012 May 9.

49.

Comparison of the effects of aliskiren/valsartan in combination versus valsartan alone in patients with stage 2 hypertension.

Flack JM, Yadao AM, Purkayastha D, Samuel R, White WB.

J Am Soc Hypertens. 2012 Mar-Apr;6(2):142-51. doi: 10.1016/j.jash.2011.11.004. Epub 2012 Feb 9.

PMID:
22321963
50.

Benefits of once-daily therapies in the treatment of hypertension.

Flack JM, Nasser SA.

Vasc Health Risk Manag. 2011;7:777-87. doi: 10.2147/VHRM.S17207. Epub 2011 Dec 21. Review.

Supplemental Content

Loading ...
Support Center